器官腫瘤晶片市場規模、佔有率和成長分析：按晶片結構、腫瘤模型類型、組成材料、應用、最終用戶和地區分類－2026-2033年產業預測

2024 年全球器官腫瘤晶片市場價值為 9,990 萬美元，預計到 2033 年將從 2025 年的 1.1538 億美元成長到 3.6543 億美元，預測期（2026-2033 年）的複合年成長率為 15.5%。

全球器官晶片市場的發展動力源自於製藥業對創新解決方案的需求，以降低並加速藥物研發風險。傳統的2D細胞培養和動物模型往往無法充分模擬人類腫瘤的生理特性，因此，人們越來越依賴微工程腫瘤晶片系統，以提高轉化準確性並最大限度地減少後期研發失敗帶來的高昂成本。微流體、3D生物列印技術和患者來源腫瘤模型的進步，正在推動開發更俱生理有效性的檢測方法，從而改善臨床決策。此外，人工智慧的整合透過提供自動化影像分析、整合分子數據和開發預測模型，提高了藥物測試的準確性，有助於識別有前景的候選藥物。這些技術的融合正在改變產業格局，並為癌症研究中的合作、標準化和減少對動物實驗的依賴創造了重要機會。

全球器官腫瘤晶片市場的成長要素

全球器官腫瘤晶片市場正受到微流體技術顯著進步的推動。該技術能夠更精確地模擬天然組織結構和流體動態。這種生理相關性的提升增強了製藥公司和學術研究人員對臨床前模型的信心，並推動其在更有效的轉化應用中得到應用。除了整合感測器和成像技術外，可容納多種細胞類型的模組化設計也促進了廣泛的研究活動和合作研究。因此，相關人員正不斷投入資源並建立夥伴關係，以利用這些創新能力進行藥物篩檢、機制闡明和生物標記發現，所有這些都推動了市場成長。

全球器官腫瘤晶片市場的限制因素

全球器官腫瘤晶片市場面臨諸多限制因素，其中之一便是開發、檢驗和規模化這些創新平台的高成本。對於小規模的實驗室和新興生物技術公司而言，對專業製造設施、嚴格的品管措施以及專業知識的需求，會導致初始投資增加和營運流程複雜化，從而造成沉重的財務負擔。這種複雜性往往促使機構進行冗長的內部評估並採取謹慎的採購方式，減緩了新技術的應用。因此，這些財務和營運方面的挑戰限制了市場滲透率，阻礙了器官腫瘤晶片解決方案的廣泛應用，儘管其優勢已得到科學證實。

全球器官腫瘤晶片市場趨勢

全球器官腫瘤晶片市場正呈現出顯著的整合趨勢，即與藥物開發平臺相融合，從而顯著提升藥物發現和最佳化過程的精準度。這些創新平台透過提供與現有篩檢方法緊密結合的、與人體相關的模型，實現了更精確的預測分析。器官晶片開發商與藥物研究人員之間日益密切的合作，使得迭代測試和化合物相互作用及作用機制的深入研究成為可能。這種合作模式不僅促進了轉化研究，還加速了候選化合物的篩選，推動了工程創新與治療目標融合的夥伴關係，並最終推動了癌症治療策略在業界的演進。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球器官腫瘤晶片市場規模：以晶片結構

• 單通道晶片
• 多通道/整合器官系統

全球器官腫瘤晶片市場規模：依腫瘤模型類型分類

• Lung Cancer-on-a-chip
• Breast Cancer-on-a-chip
• 大腸直腸癌和肝癌模型

全球器官腫瘤晶片市場規模：依組件材料分類

• 聚二甲基矽氧烷（PDMS）基體
• 熱塑性樹脂/水凝膠平台

全球器官腫瘤晶片市場規模：按應用領域分類

• 藥物發現和療效測試
• 個人化癌症治療（患者來源細胞）
• 毒理學和安全性評估
• 癌症基礎研究與轉移研究

全球器官腫瘤晶片市場規模：依最終用戶分類

• 藥物和生物技術研發
• 學術研究機構
• 受託研究機構（CRO）

全球器官腫瘤晶片市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要企業2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要企業的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要企業簡介

• Emulate Inc.
• Mimetas
• InSphero AG
• TissUse GmbH
• Organovo
• Axosim
• Beonchip
• BioIVT
• Nortis Inc.
• CN Bio Innovations
• Hesperos Inc.
• AlveoliX
• Dynamic42
• Netri
• MesoBioTech
• SynVivo
• Cherry Biotech
• BiomimX
• Elveflow
• Fluigent

結論與建議

Global Organ Tumor Chip Market size was valued at USD 99.9 Million in 2024 and is poised to grow from USD 115.38 Million in 2025 to USD 365.43 Million by 2033, growing at a CAGR of 15.5% during the forecast period (2026-2033).

The global organ tumor chip market is driven by the pharmaceutical industry's demand for innovative solutions to de-risk and expedite drug development. Traditional two-dimensional cell cultures and animal models are often inadequate in mimicking human tumor physiology, prompting an increasing reliance on microengineered tumor-on-chip systems that enhance translational accuracy and minimize costly late-stage failures. With advancements in microfluidics, 3D bioprinting, and patient-derived tumor models, these technologies foster more physiologically relevant assays that improve clinical decision-making. Additionally, the integration of AI enhances drug testing accuracy by providing automated image analyses, integrating molecular data, and developing predictive models that help identify promising drug candidates. This convergence of technologies is reshaping the landscape, leading to significant opportunities for collaboration, standardization, and the reduction of animal study dependence in oncology research.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Organ Tumor Chip market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Organ Tumor Chip Market Segments Analysis

Global organ tumor chip market is segmented by chip architecture, tumor model type, component material, application domain, end-user and region. Based on chip architecture, the market is segmented into Single-channel Chips and Multi-channel/Integrated Organ Systems. Based on tumor model type, the market is segmented into Lung Cancer-on-a-chip, Breast Cancer-on-a-chip and Colorectal/Liver Cancer Models. Based on component material, the market is segmented into PDMS (Polydimethylsiloxane) based and Thermoplastic/Hydrogel Platforms. Based on application domain, the market is segmented into Drug Discovery & Efficacy Testing, Personalized Cancer Medicine (Patient-derived cells), Toxicology & Safety Assessment and Basic Cancer Research & Metastasis Studies. Based on end-user, the market is segmented into Pharmaceutical & Biotech R&D, Academic Research Institutes and Contract Research Organizations (CROs). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Organ Tumor Chip Market

The Global Organ Tumor Chip market is being propelled forward by significant advancements in microfluidic technology, which have allowed for the more accurate imitation of natural tissue structures and fluid dynamics. This heightened physiological authenticity boosts the trust that pharmaceutical companies and academic researchers place in preclinical models, driving their adoption for more effective translational applications. The incorporation of sensors and imaging technologies, along with modular designs that accommodate various cell types, fosters a wide range of research endeavors and collaboration. Consequently, stakeholders are increasingly committing resources and forming partnerships to harness these innovative capabilities for drug screening, mechanistic investigations, and biomarker discovery, all of which contribute to the market's growth.

Restraints in the Global Organ Tumor Chip Market

The Global Organ Tumor Chip market faces considerable restraints due to high costs linked to the development, standardized validation, and scaling of these innovative platforms. Smaller research laboratories and emerging biotech companies may struggle with the financial demands, as the requirement for specialized fabrication facilities, stringent quality control measures, and expertise increases initial investments and complicates operational processes. This complexity tends to slow down the adoption of new technologies, as institutions often engage in prolonged internal evaluations and adopt cautious procurement approaches. Consequently, these financial and operational challenges limit market penetration and impede the widespread acceptance of organ tumor chip solutions, despite their proven scientific benefits.

Market Trends of the Global Organ Tumor Chip Market

The Global Organ Tumor Chip market is witnessing a significant trend toward integration into pharmaceutical development pipelines, enhancing the precision of drug discovery and optimization processes. By offering human-relevant models that align closely with existing screening practices, these innovative platforms facilitate more accurate predictive analyses. The collaboration between organ chip developers and pharmaceutical researchers is expanding, enabling iterative testing and deeper investigations into compound interactions and mechanisms. This collaborative approach not only bolsters translational research but also accelerates candidate selection and fosters partnerships that harmonize engineering innovations with therapeutic objectives, ultimately driving the evolution of cancer treatment strategies in the industry.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Organ Tumor Chip Market Size by Chip Architecture & CAGR (2026-2033)

• Market Overview
• Single-channel Chips
• Multi-channel/Integrated Organ Systems

Global Organ Tumor Chip Market Size by Tumor Model Type & CAGR (2026-2033)

• Market Overview
• Lung Cancer-on-a-chip
• Breast Cancer-on-a-chip
• Colorectal/Liver Cancer Models

Global Organ Tumor Chip Market Size by Component Material & CAGR (2026-2033)

• Market Overview
• PDMS (Polydimethylsiloxane) based
• Thermoplastic/Hydrogel Platforms

Global Organ Tumor Chip Market Size by Application Domain & CAGR (2026-2033)

• Market Overview
• Drug Discovery & Efficacy Testing
• Personalized Cancer Medicine (Patient-derived cells)
• Toxicology & Safety Assessment
• Basic Cancer Research & Metastasis Studies

Global Organ Tumor Chip Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical & Biotech R&D
• Academic Research Institutes
• Contract Research Organizations (CROs)

Global Organ Tumor Chip Market Size & CAGR (2026-2033)

• North America (Chip Architecture, Tumor Model Type, Component Material, Application Domain, End-User)
  • US
  • Canada
• Europe (Chip Architecture, Tumor Model Type, Component Material, Application Domain, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Chip Architecture, Tumor Model Type, Component Material, Application Domain, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Chip Architecture, Tumor Model Type, Component Material, Application Domain, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Chip Architecture, Tumor Model Type, Component Material, Application Domain, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Emulate Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mimetas
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InSphero AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TissUse GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organovo
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axosim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beonchip
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioIVT
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nortis Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CN Bio Innovations
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hesperos Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AlveoliX
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynamic42
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Netri
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MesoBioTech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SynVivo
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cherry Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BiomimX
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elveflow
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fluigent
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations